Zhao Jia-Ming, An Qi, Sun Chao-Nan, Li Yu-Bing, Qin Zi-Lan, Guo Hong, Zeng Xue, Zhang Yao-Tian, Wei Lin-Lin, Han Ning, Sun Shi-Chen, Zhang Na
Department of Radiation Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang, 110042, Liaoning Province, China.
Breast Cancer. 2021 Mar;28(2):298-306. doi: 10.1007/s12282-020-01158-0. Epub 2020 Sep 17.
The purpose of this study was to identify independent prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes, and discuss the role of postmastectomy radiotherapy(PMRT) in these patients.
Between January 2005 and December 2015, the data on 840 eligible patients with breast cancer were retrospectively reviewed. Of these patients, 368 women received PMRT and 472 did not. The endpoints were locoregional recurrence (LRR) and distant metastasis (DM).
With a median follow-up of 62.0 months, multivariate analysis identified the following independent risk factors for increased LRR: tumor size ≥ 4 cm (HR: 2.994, 95% CI: 1.190-7.535, P = 0.020), ER- and PR-negative tumor (HR: 2.540, 95% CI: 1.165-5.537, P = 0.019), preoperative high neutrophil-to-lymphocyte ratio (NLR) (HR: 4.716, 95% CI: 1.776-12.528, P = 0.002)and low neutrophil-to-monocyte ratio (NMR) (HR: 0.231, 95% CI: 0.084-0.633, P = 0.004). And independent risk factors for increased DM: ER- and PR-negative tumor (HR: 2.540, 95% CI: 1.880-5.625, P = 0.000), high NLR (HR: 2.693, 95% CI: 1.426-5.084, P = 0.002) and low NMR (HR: 0.460, 95% CI: 0.257-0.824, P = 0.009). The high-risk patients (≥ 2 risk factors) had worse LRRFS and DFS than low-risk patients (0-1 risk factor) (all, P < 0.05). In the subgroup analysis, both low- and high-risk patients received PMRT had better LRRFS and DFS than those who without PMRT (all, P < 0.05), and the high-risk patients received PMRT had similar 5-year rates of LRRFS and DFS than low-risk patients who without PMRT (94.5 vs. 94.3%, P = 0.402; 83.4 vs.87.4%, P = 0.877, respectively).
Tumor size, ER/PR status, preoperative NLR and NMR were independent predictors of risk of recurrence. PMRT could improve locoregional control even in low-risk subgroup of breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes significantly.
本研究旨在确定T1-2期肿瘤且有1-3枚阳性淋巴结的乳腺癌患者的独立预后因素,并探讨乳房切除术后放疗(PMRT)在这些患者中的作用。
回顾性分析2005年1月至2015年12月期间840例符合条件的乳腺癌患者的数据。其中,368例女性接受了PMRT,472例未接受。观察终点为局部区域复发(LRR)和远处转移(DM)。
中位随访62.0个月,多因素分析确定了以下LRR增加的独立危险因素:肿瘤大小≥4 cm(HR:2.994,95%CI:1.190-7.535,P = 0.020)、雌激素受体(ER)和孕激素受体(PR)阴性肿瘤(HR:2.540,95%CI:1.165-5.537,P = 0.019)、术前高中性粒细胞与淋巴细胞比值(NLR)(HR:4.716,95%CI:1.776-12.528,P = 0.002)和低中性粒细胞与单核细胞比值(NMR)(HR:0.231,95%CI:0.084-0.633,P = 0.004)。以及DM增加的独立危险因素:ER和PR阴性肿瘤(HR:2.540,95%CI:1.880-5.625,P = 0.000)、高NLR(HR:2.693,95%CI:1.426-5.084,P = 0.002)和低NMR(HR:0.460,95%CI:0.257-0.8